ilmscore | Prediction Details
"The company is allocating 400 CR for next-generation RADs ranging from small molecules to cell and gene therapies."
By Groww | June 25, 2025 | Pending
From video
3 Stocks With Better Fundamentals Than Their Valuation 00:12:12 - 00:12:20
Interpreted Prediction
Natco Pharma is allocating ₹400 crore for next-generation R&D, focusing on small molecules, cell, and gene therapies.

Prediction Details

Ticker
NATCOPHARM

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.